Table 4 Univariable and multivariable analyses for the prognosis of patients with cT1 NSCLC

Age

1.02 (1.01–1.04)

0.002

1.03 (1.01–1.04)

0.003

Female vs. Male

0.50 (0.38–0.67)

< 0.001

0.66 (0.47–0.94)

0.020

Smoking

1.97 (1.44–2.70)

< 0.001

1.07 (0.72–1.58)

0.742

ASA score

 P2 vs. P1

1.16 (0.84–1.60)

0.355

 P3 vs. P1

1.46 (0.92–2.31)

0.109

Hypertension

1.12 (0.83–1.50)

0.475

Diabetes

1.10 (0.70–1.72)

0.677

Coronary heart disease

1.10 (0.62–1.93)

0.748

Chronic respiratory diseases

0.70 (0.29–1.70)

0.432

SN vs. PSN

5.82 (4.07–8.31)

< 0.001

2.92 (1.59–5.34)

< 0.001

Solid size

3.02 (2.46–3.70)

< 0.001

1.25 (1.04–1.73)

0.036

Tumor location

0.395

 RUL

Reference

/

 RML

1.09 (0.62–1.93)

0.763

 RLL

1.20 (0.77–1.86)

0.422

 LUL

1.04 (0.70–1.55)

0.831

 LLL

1.48 (0.99–2.21)

0.055

Lobectomy. vs. Sublobar

3.35 (2.03–5.52)

< 0.001

1.36 (0.80–2.31)

0.251

Histological types

0.004

0.267

 ADC

Reference

Reference

/

 Others

2.54 (1.30–4.98)

0.007

1.58 (0.80–3.13)

0.191

 SCC

2.36 (1.28–4.34)

0.006

0.72 (0.37–1.40)

0.335

Lymph node metastasis

9.57 (7.18–12.77)

< 0.001

3.19 (2.23–4.55)

< 0.001

Evaluated lymph nodes

1.04 (1.01–1.07)

0.002

1.01 (0.98–1.03)

0.667

Pleura invasion

2.68 (1.94–3.68)

< 0.001

1.04 (0.73–1.47)

0.839

EGFR

0.77 (0.47–1.26)

0.296

ALK fusion

1.58 (0.21–11.63)

0.655

ROS1 fusion

0 (0-Inf)

0.997

Adjuvant therapy

3.93 (2.15–6.32)

< 0.001

1.72 (0.85–3.01)

0.237